LogicBio Therapeutics Inc
NASDAQ. Currency in USD
2.07 +0.01 ( +0.49% )
Beta (5Y monthly)
1y Target Est.
52 Week's Range
About LogicBio Therapeutics Inc
65 Hayden Avenue, Lexington, MA, United States, 02421
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
The Zacks Analyst Blog highlights Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs
Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs are part of the...
By Zacks Investment Research - 17 weeks ago